Patents Represented by Attorney Ginger R. Dreger

Find this attorney in the Justia Lawyer Directory

  • Treatment with anti-ErbB2 antibodies
    Patent number: 7846441
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: December 7, 2010
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • Antibody fragment-peg conjugates
    Patent number: 7005504
    Abstract: Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: February 28, 2006
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata
  • Treatment of balance impairments
    Patent number: 6974798
    Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of balance impairments involving neuronal damage, loss, or degeneration, preferably of vestibular ganglion neurons, in an animal by administration of an effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: December 13, 2005
    Assignee: Genentech, Inc.
    Inventor: Wei-Qiang Gao
  • Isolation of neurotrophins from a mixture containing neurotrophin variants using hydrophobic interaction chromatography
    Patent number: 6953844
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: October 11, 2005
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Therapeutic use of cis-element decoys in vivo
    Patent number: 6821956
    Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: November 23, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
  • Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
    Patent number: 6818446
    Abstract: The invention relates to compositions and methods for the assessment of mucin gene expression. The invention also relates to compositions and methods for the identification of compounds useful in the treatment of various disorders caused by mucin overproduction. The invention provides novel MUC5B promoter sequences and reporter constructs comprising these MUC5B promoter sequences. The invention further provides methods for drug screening to identify compounds have the ability to inhibit MUC5B gene expression. Compounds having the ability to inhibit MUC5B gene expression find use in the treatment of diseases characterized by mucin hyperproduction.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: November 16, 2004
    Assignee: The Regents of the University of California
    Inventors: Reen Wu, Yin Chen
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 6818449
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: November 16, 2004
    Assignee: Genentech, Inc.
    Inventors: Sherman Fong, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
    Patent number: 6811966
    Abstract: The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins.
    Type: Grant
    Filed: January 11, 2002
    Date of Patent: November 2, 2004
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 6806352
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: October 19, 2004
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Modified green fluorescent proteins
    Patent number: 6800733
    Abstract: Modifications in the sequence of Aequorea wild-type GFP provide products having markedly different excitation and emission spectra from corresponding products from wild-type GFP. In one class of modifications, the product derived from the modified GFP exhibits an alteration in the ratio of two main excitation peaks observed with the product derived from wild-type GFP. In another class, the product derived from the modified GFP fluoresces at a shorter wavelength than the corresponding product from wild-type GFP. In yet another class of modifications, the product derived from the modified GFP exhibits only a single excitation peak and enhanced emission relative to the product derived from wild-type GFP.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: October 5, 2004
    Assignee: The Regents of the University of California
    Inventors: Roger Y. Tsien, Roger Heim
  • Neurturin receptor
    Patent number: 6777196
    Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: August 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
  • Identification of sortase gene
    Patent number: 6773706
    Abstract: The present invention is a substantially purified sortase-transamidase enzyme from Gram-positive bacteria, such as Staphylococcus aureus.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: August 10, 2004
    Assignee: The Regents of the University of California
    Inventors: Olaf Schneewind, Sarkis Mazmanian, Gwen Liu, Hung Ton-That
  • Therapeutic use of CIS-element decoys in vivo
    Patent number: 6774118
    Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: August 10, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
  • Insulin-like growth factor agonist molecules
    Patent number: 6743894
    Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: June 1, 2004
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F Robinson, Nicholas J. Skelton
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 6723535
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: April 20, 2004
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Jennie P. Mather, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
  • Insulin-like growth factor agonist molecules
    Patent number: 6716586
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 6, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6713451
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 30, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6693079
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6693078
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6689751
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 10, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson